HALO

Halozyme Therapeutics (HALO)

Halozyme Therapeutics Incorporated

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:HALO

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/08	21:30	PR Newswire (US)	Halozyme to Participate in Upcoming Investor Conferences	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/05/08	05:09	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/05/08	05:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/05/08	05:01	PR Newswire (US)	HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/04/26	05:45	PR Newswire (US)	Mahesh Krishnan Elected to Halozyme's Board of Directors	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/04/23	21:30	PR Newswire (US)	Halozyme to Report First Quarter 2024 Financial and Operating Results	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/03/05	06:13	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/29	08:49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/29	06:07	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/28	07:12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/28	07:05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/28	07:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/28	06:08	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/27	22:30	PR Newswire (US)	Halozyme to Participate in Upcoming Investor Conferences	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/21	08:59	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/21	08:55	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/21	08:53	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/21	08:49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/21	06:07	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/21	06:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/21	06:01	PR Newswire (US)	HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/17	07:47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/17	07:41	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/17	07:39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/14	06:18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/14	06:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/14	06:12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/12	20:19	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/09	06:30	PR Newswire (US)	Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/01/30	06:15	PR Newswire (US)	Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	NASDAQ:HALO	Halozyme Therapeutics Incorporated